Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

Mar 1, 2019

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

Feb 19, 2019

Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium

Feb 6, 2019

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types

Feb 4, 2019

Rexahn Announces Pricing of Public Offering of Common Stock and Warrants

Jan 23, 2019

Rexahn Announces Proposed Public Offering of Common Stock and Warrants

Jan 22, 2019

Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium

Jan 22, 2019

Rexahn Announces Presentation of RX-3117 Data at the 2019 ASCO Gastrointestinal Cancers Symposium

Jan 14, 2019

Rexahn Pharmaceuticals Streamlines Operations and Provides Update on Pipeline

Dec 6, 2018

Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors

Dec 3, 2018